The transcriptional repressor Snail promotes mammary tumor recurrence

Bachelder, 2005, Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implication for the epithelial-mesenchymal transition, J. Cell Biol., 168, 29, 10.1083/jcb.200409067 Baselga, 1996, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, J. Clin. Oncol., 14, 737, 10.1200/JCO.1996.14.3.737 Batlle, 2000, The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells, Nat. Cell Biol., 2, 84, 10.1038/35000034 Berger, 1988, Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading, Cancer Res., 48, 1238 Blanco, 2002, Correlation of Snail expression with histological grade and lymph node status in breast carcinomas, Oncogene, 21, 3241, 10.1038/sj.onc.1205416 Cano, 2000, The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression, Nat. Cell Biol., 2, 76, 10.1038/35000025 Cardiff, 1991, Transgenic oncogene mice. Tumor phenotype predicts genotype, Am. J. Pathol., 139, 495 Carter, 1989, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, 63, 181, 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H Carver, 2001, The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition, Mol. Cell. Biol., 21, 8184, 10.1128/MCB.21.23.8184-8188.2001 Cheng, 2001, Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene, Oncogene, 20, 3814, 10.1038/sj.onc.1204505 Demicheli, 2004, Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour, Breast Cancer Res., 6, R689, 10.1186/bcr937 Doyle, 2001, Long-term results of local recurrence after breast conservation treatment for invasive breast cancer, Int. J. Radiat. Oncol. Biol. Phys., 51, 74, 10.1016/S0360-3016(01)01625-X Esteva, 2004, Prognostic molecular markers in early breast cancer, Breast Cancer Res., 6, 109, 10.1186/bcr777 Fisher, 1991, Significance of ipsilateral breast tumour recurrence after lumpectomy, Lancet, 338, 327, 10.1016/0140-6736(91)90475-5 Fisher, 2004, Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials, Lancet, 364, 858, 10.1016/S0140-6736(04)16981-X Fortin, 1999, Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy, J. Clin. Oncol., 17, 101, 10.1200/JCO.1999.17.1.101 Fuchs, 2002, The prognostic significance of epithelial-mesenchymal transition in breast cancer, Anticancer Res., 22, 3415 Gamallo, 1993, Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma, Am. J. Pathol., 142, 987 Grau, 1984, Mutations and chromosomal rearrangements affecting the expression of snail, a gene involved in embryonic patterning in Drosophila melanogaster, Genetics, 108, 347, 10.1093/genetics/108.2.347 Gunther, 2002, A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology, FASEB J., 16, 283, 10.1096/fj.01-0551com Guriec, 1996, E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival, Invasion Metastasis, 16, 19 Hajra, 2002, The SLUG zinc-finger protein represses E-cadherin in breast cancer, Cancer Res., 62, 1613 Heimann, 2000, Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin, Cancer Res., 60, 298 Hortobagyi, 2001, Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer, Semin. Oncol., 28, 43, 10.1016/S0093-7754(01)90108-3 Ma, 2004, A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen, Cancer Cell, 5, 607, 10.1016/j.ccr.2004.05.015 Moody, 2002, Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis, Cancer Cell, 2, 451, 10.1016/S1535-6108(02)00212-X Niveditha, 2003, Vimentin expression in breast carcinomas, Indian J. Pathol. Microbiol., 46, 579 Pantel, 2003, Detection and clinical implications of early systemic tumor cell dissemination in breast cancer, Clin. Cancer Res., 9, 6326 Parkin, 2005, Global cancer statistics, 2002, CA Cancer J. Clin., 55, 74, 10.3322/canjclin.55.2.74 Saphner, 1996, Annual hazard rates of recurrence for breast cancer after primary therapy, J. Clin. Oncol., 14, 2738, 10.1200/JCO.1996.14.10.2738 Schlotter, 2003, c-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer, Breast Cancer Res., 5, R30, 10.1186/bcr568 Schmoor, 2000, Role of isolated locoregional recurrence of breast cancer: results of four prospective studies, J. Clin. Oncol., 18, 1696, 10.1200/JCO.2000.18.8.1696 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101 Soo, 2002, Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo, Dev. Biol., 247, 251, 10.1006/dbio.2002.0699 Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad. Sci. USA, 98, 10869, 10.1073/pnas.191367098 Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc. Natl. Acad. Sci. USA, 100, 8418, 10.1073/pnas.0932692100 Tang, 2000, The Akt proto-oncogene links Ras to Pak and cell survival signals, J. Biol. Chem., 275, 9106, 10.1074/jbc.275.13.9106 Valagussa, 1978, Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients, Cancer, 41, 1170, 10.1002/1097-0142(197803)41:3<1170::AID-CNCR2820410355>3.0.CO;2-I van’t Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 719, 10.1200/JCO.20.3.719 Wang, 2001, Targeting HER2: recent developments and future directions for breast cancer patients, Semin. Oncol., 28, 21, 10.1053/sonc.2001.29724 Wang, 2005, Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Lancet, 365, 671, 10.1016/S0140-6736(05)70933-8 Weiss, 2003, Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B, J. Clin. Oncol., 21, 1825, 10.1200/JCO.2003.09.006 Yang, 2004, Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis, Cell, 117, 927, 10.1016/j.cell.2004.06.006 Yang, 2005, Pak1 phosphorylation of Snail, a master regulator of epithelial-to-mesenchymal transition, modulates Snail’s subcellular localization and function, Cancer Res., 65, 3179, 10.1158/0008-5472.CAN-04-3480 Zhou, 2004, Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition, Nat. Cell Biol., 6, 931, 10.1038/ncb1173